<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C35E3A25-DD95-4B59-9D2B-862A94477483"><gtr:id>C35E3A25-DD95-4B59-9D2B-862A94477483</gtr:id><gtr:name>Lein Applied Diagnostics Limited</gtr:name><gtr:address><gtr:line1>Reading Enterprise Centre
Earley Gate
Whiteknights Road</gtr:line1><gtr:city>Reading</gtr:city><gtr:postCode>RG6 6BU</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C35E3A25-DD95-4B59-9D2B-862A94477483" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>C35E3A25-DD95-4B59-9D2B-862A94477483</gtr:id><gtr:name>Lein Applied Diagnostics Limited</gtr:name><gtr:address><gtr:line1>Reading Enterprise Centre
Earley Gate
Whiteknights Road</gtr:line1><gtr:city>Reading</gtr:city><gtr:postCode>RG6 6BU</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>24960.0</gtr:offerGrant><gtr:projectCost>41600.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E55733ED-3B3C-48D0-8625-9A2505804BCA"><gtr:id>E55733ED-3B3C-48D0-8625-9A2505804BCA</gtr:id><gtr:firstName>Dan</gtr:firstName><gtr:surname>Daly</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700560"><gtr:id>85481570-8401-4504-92F8-5608898DC005</gtr:id><gtr:title>In situ 3D diffusion tracking for biomedical materials</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700560</gtr:grantReference><gtr:abstractText>In the healthcare screening sectors (drug discovery &amp;amp; biomedical materials) there is a pressing
need for new quantitative monitoring technologies for in-vitro testing. Artificial 3D tissues,
often in the form of 3D constructs such as liver mimics, are used to replicate the behaviour of
real tissue and to track the diffusion of compounds, pharma-active species and cells in
laboratory trials, thus improving the drug discovery process. However, their uptake has been
limited by the inability to quantitatively measure the diffusion in real-time, non-invasively and
cost effectively.
Lein has combined its innovative scanning confocal technology, that is highly accurate, cost
effective and very compact, with a fluorescence capability that enables the concentration of a
compound to be detected at low nanomolar concentrations. This technology has been
incorporated in a practical meter so that clinical researchers can assess the concentration of,
and movement of, compounds within biological media. The strength of the meter is that it is
able to make non-contact measurements enabling dynamic, in-situ testing.
In this project Lein will analyse markets for this new technology. Relevant Key Opinion
Leaders (academia, pharma companies, specialist life science companies) and potential
customers will be interviewed and market needs, dynamics, drivers, barriers, competition, and
potential size analysed to build a clear picture of the market opportunity. The outputs will be
used to create a commercial exploitation plan, including market strategy and routes to market,
and underpin the product development and funding raising plans.</gtr:abstractText><gtr:fund><gtr:end>2015-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>24960</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700560</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>